Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

NCT01709513 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

314

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia

Interventions

DRUG: Atorvastatin
DRUG: Ezetimibe
DRUG: Alirocumab
DRUG: Placebo

Sponsor

Regeneron Pharmaceuticals

Collaborators

[object Object]